Recent Research Funding

Faculty secure several million dollars annually for their research from various public and private sources, including the National Institutes of Health, U.S. Food and Drug Administration, National Multiple Sclerosis Society, foundations and pharmaceutical firms.

  • MRI-Based Quantitative Mapping of Oxygen Extraction Fraction in MS. Ferdinand Schweser (Co-Investigator). NIBIB. $1,773,283. 4/1/2024-3/1/2029.
  • A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis, BEAT-MS (Protocol ITN077AI). Bianca Weinstock-Guttman (Principal Investigator). National Institute of Allergy & Infectious Diseases (NIAID), Division of Allergy, Immunology &Transplantation (DAIT) via a subaward. 1/1/2020-12/1/2026.
  • Clinical, Genetic, and Cellular Consequences of Mutations in Na, K-ATP1A3. Allison Brashear (Principal Investigator). NINDS. $8,808,869. 4/1/2008-6/1/2026.
  • Lung-brain coupling and the immune response to acute ischemic stroke. Marc Halterman (Principal Investigator). NIH/NINDS. 5/1/2021-6/1/2026.
  • Optimizing Chest Compressions Targeting Gas Exchange and Hemodynamics in a Transitional Cardiac Arrest Model. Ferdinand Schweser (Co-Investigator). National Institutes of Health. $1,642,389. 4/1/2021-3/1/2026.
  • A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063). Bianca Weinstock-Guttman (Principal Investigator). Celgene International. 6/1/2020-12/1/2025.
  • Neural indices of cognitive decline and cognitive resiliency in people with neurological disturbances. Thomas Covey (Principal Investigator). National Institutes of Health. $28,321. 10/1/2023-10/1/2025.
  • Deep gray matter iron and disease progression in multiple sclerosis. Ferdinand Schweser (Principal Investigator). National Institutes of Health. $1,808,000. 7/1/2021-6/1/2025.
  • Buffalo Bioimaging Brain Bank for Neurological Disorders (B4ND). Ferdinand Schweser (Principal Investigator). $68,000. 6/1/2024-6/1/2025.
  • Repurposing lithium as a disease-modifying therapy in Parkinson’s disease: A Randomized Controlled Trial. Thomas Guttuso, Jr. (Principal Investigator). Cure Parkinson's Trust. $242,272. 5/1/2024-4/1/2025.
  • NeuroTag: GFP-tagging the ER-stress proteome to address bottlenecks in stroke therapeutics discovery. Marc Halterman (Principal Investigator). SUNY Research Foundation. 3/1/2023-3/1/2025.
  • Feasibility of the Multiple Sclerosis Performance Test for assessment of functional performance measures in patients with Multiple Sclerosis (US-MSG-18-11424). Bianca Weinstock-Guttman (Principal Investigator). Biogen. 6/1/2019-12/1/2024.
  • Buffalo Clinical and Translational Research Center. Ferdinand Schweser (Co-Investigator). National Institutes of Health. $19,101,902. 2/1/2020-12/1/2024.
  • Advanced imaging assessment of underserved relapsing and progressive multiple sclerosis patients: a case-control study. Ferdinand Schweser (Co-Investigator). $67,000. 1/1/2024-12/1/2024.
  • Assessing the Efficacy of Alterations in Subcortical-Cortical Functional Connectivity from Transcranial Direct Current Stimulation in Older Children after Mild Traumatic Brain Injury. Ferdinand Schweser (Co-Principal Investigator). $54,380. 1/1/2024-12/1/2024.
  • NeuroTag: GFP-tagging the ER-stress proteome to address bottlenecks in stroke therapeutics discovery. Marc Halterman (Co-Principal Investigator). Stony Brook OVPR Seed Program. 4/1/2023-10/1/2024.
  • Investigation of behavioral and neural indices of multisensory information processing in Multiple Sclerosis: A novel approach. Thomas Covey (Principal Investigator). Department of Defense Multiple Sclerosis Research Program. $232,022. 9/1/2021-9/1/2024.
  • Buffalo Clinical and Translational Research Center. Kinga Szigeti (Co-Investigator). NIH/NCATS. 7/1/2019-7/1/2024.
  • Phase 3 randomized, double blind, placebo-controlled multicenter study to evaluate satralizumab in generalized myasthenia gravis (LUMINESCE). Gil Wolfe (Co-Investigator). Roche. 1/1/2021-3/1/2024.
  • Investigation of behavioral and neural indices of multisensory information processing in Multiple Sclerosis: A novel approach. Exploration -hypothesis development award. David Shucard (Co-Investigator). Department of Defense Multiple Sclerosis Research Program. $232,022. 10/1/2021-10/1/2023.